Download presentation
Presentation is loading. Please wait.
Published byShyanne Ventre Modified over 9 years ago
1
Clinical bioequivalence
2
Specific example n A manufacturer wishes to change its approved production method for standardized fedweed pollen extract n CBER acknowledges that existing in vitro potency tests will be applicable to the new preparation. However, CBER requests that the manufacturer demonstrate compositional similarity by parallel line bioassay
3
Clinical bioequivalence
5
“At least 4 subjects are required per assay. One or more test extracts are to be compared against a reference in each subject. For evaluating compositional differences, subjects…selectively sensitive to specific allergens in the crude mix should be selected…[I]n order to enhance detection of compositional differences, subjects can be selected who differ widely (10-10,000 fold) in their allergen skin test sensitivity…to the test of reference extracts.”
9
Manufacturer proposal n Based on the 1993 protocol, the manufacturer proposes to enlist 4 to 6 study subjects of varying levels of sensitivity to fedweed pollen n If the slopes of the two preparations are not significantly different in these study subjects, the manufacturer will conclude that the two preparations are compositionally similar
10
Initial assumptions n Mean slope: 10 n Acceptable difference: 10% = 1 n SD slope: 1 n = 0.05 = 0.2 = 0.2
12
To determine the number of subjects (n) required to detect a difference with confidence and power 1 - with the two one-sided test approach, use the following:
13
For = 0.05 and = 0.2:
15
Conclusions n The failure to demonstrate a difference is not sufficient to demonstrate equivalence Given that, for the parallel line bioassay, , the number of study subjects required to demonstrate equivalence will usually exceed 4-6 Given that, for the parallel line bioassay, , the number of study subjects required to demonstrate equivalence will usually exceed 4-6
16
Advisory Committee discussion CBER requests that the Committee discuss CBER’s current approach to clinical bioequivalence studies as it applies to allergen extract studies.
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.